For patients · Medication guide

Pegloticase

pegloticase, Krystexxa

Are you a clinician? See the clinical version of this page.

The short versionPegloticase is a strong uric-acid-lowering treatment given by a drip into a vein. It is reserved for severe gout with many crystal lumps that has not responded to the usual tablets.
How you take it

Given as a drip into a vein every 2 weeks, for severe gout that has not responded to other medicines. You will be checked for a blood condition (G6PD deficiency) first and given medicines to prevent reactions. Your uric acid is checked before each dose.

Tests while you take it

You will be watched during and after each infusion for reactions. Your uric acid is checked before each dose.

What to know

How it is used in gout

Pegloticase is only used for severe gout with tophi that the usual medicines have not controlled. It is not a first medicine, and it involves regular infusions.

Before starting

You will be checked before starting, including a blood test for a condition called G6PD deficiency, because pegloticase is not safe if you have it.

Monitoring

Your uric acid is checked before infusions. A rising level can signal that the medicine is no longer working and that reactions are more likely, so treatment may be stopped.

Common effects

Infusion reactions and gout attacks are common. Attacks can increase when starting, as with other uric-acid-lowering treatments.

Important cautions

Serious allergic reactions can happen during or after the infusion, which is why it is given where staff can respond. It is not used if you have G6PD deficiency.

iThis page helps you prepare a conversation with your care team. It does not replace individual medical advice. Always confirm your own plan with your rheumatology team.
!

What to watch for